EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Lazertinib plus pemetrexed and carboplatin in patients with EGFR-mutant advanced non-small cell lung cancer after progression on lazertinib

Min Hee Hong, Byoung Yong Shim, Chang Gon Kim, Young Saing Kim, Seoyoung Lee, Youngjoo Lee, Beung-Chul Ahn, Myung-Ju Ahn, Jin Seok Ahn, Sehhoon Park, Ja Hyun Yeo, Sook Hee Hong und 3 weitere

European Journal of Cancer · 2026-11 · 248 · 117774

DOI: 10.1016/j.ejca.2026.117774 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Min Hee Hong und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Yonsei University College of Medicine, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungLung NeoplasmsPemetrexedAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDisease ProgressionErbB ReceptorsMutationProgression-Free SurvivalTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

Chemotherapy combinationCirculating tumor DNAEGFR-TKI continuationEGFR-mutant NSCLCIntracranial efficacyLazertinib

Substanzen

CarboplatinEGFR protein, humanErbB ReceptorsPemetrexedTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, 222 Banpodaero, Seoul, Republic of Korea.
  • Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.
  • Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Förderung

  • Yonsei University College of Medicine
  • National Research Foundation of Korea

Zitieren

APA

Hong, M. H., Shim, B. Y., Kim, C. G., Kim, Y. S., Lee, S., Lee, Y., Ahn, B. C., Ahn, M. J., Ahn, J. S., Park, S., Yeo, J. H., Hong, S. H., Jang, I. H., Lee, K. H., & Kim, H. R. (2026). Lazertinib plus pemetrexed and carboplatin in patients with EGFR-mutant advanced non-small cell lung cancer after progression on lazertinib. European Journal of Cancer, 248, 117774. https://doi.org/10.1016/j.ejca.2026.117774

Vancouver

Hong MH, Shim BY, Kim CG, Kim YS, Lee S, Lee Y, et al. Lazertinib plus pemetrexed and carboplatin in patients with EGFR-mutant advanced non-small cell lung cancer after progression on lazertinib. European Journal of Cancer. 2026;248:117774. doi:10.1016/j.ejca.2026.117774

BibTeX
@article{Hong2026,
  author = {Hong, Min Hee and Shim, Byoung Yong and Kim, Chang Gon and Kim, Young Saing and Lee, Seoyoung and Lee, Youngjoo and Ahn, Beung-Chul and Ahn, Myung-Ju and Ahn, Jin Seok and Park, Sehhoon and Yeo, Ja Hyun and Hong, Sook Hee and Jang, In Hwan and Lee, Ki Hyeong and Kim, Hye Ryun},
  title = {Lazertinib plus pemetrexed and carboplatin in patients with EGFR-mutant advanced non-small cell lung cancer after progression on lazertinib},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117774},
  doi = {10.1016/j.ejca.2026.117774}
}
Kostenlos starten →